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Abstract
Background: Drug resistance is one of the major obstacles limiting the activity of anticancer agents. Activation of
DNA repair mechanism often accounts for increase resistance to cancer chemotherapy.
Results: We present evidence that nemorubicin, a doxorubicin derivative currently in clinical evaluation, acts
through a mechanism of action different from classical anthracyclines, requiring an intact nucleotide excision repair
(NER) system to exert its activity. Cells made resistant to nemorubicin show increased sensitivity to UV damage. We
have analysed the mechanism of resistance and discovered a previously unknown mechanism resulting from
methylation-dependent silencing of the XPG gene. Restoration of NER activity through XPG gene transfer or
treatment with demethylating agents restored sensitivity to nemorubicin. Furthermore, we found that a significant
proportion of ovarian tumors present methylation of the XPG promoter.
Conclusions: Methylation of a NER gene, as described here, is a completely new mechanism of drug resistance
and this is the first evidence that XPG gene expression can be influenced by an epigenetic mechanism. The
reported methylation of XPG gene could be an important determinant of the response to platinum based therapy.
In addition, the mechanism of resistance reported opens up the possibility of reverting the resistant phenotype
using combinations with demethylating agents, molecules already employed in the clinical setting.
Background
Drug resistance is one of the major obstacles limiting
the effectiveness of cancer therapy [1-3]. Understanding
the specific mechanisms of resistance to a given drug
and the possibility of reversing the resistant phenotype
are of pivotal importance.
It is generally accepted that DNA damaging agents
show greater activity when there are defects in DNA
repair. Exceptions are trabectedin, a marine compound
currently under clinical investigation [4-7] that is less
active in cells with deficient nucleotide excision repair
(NER) [8,9] and cisplatin and carboplatin, two widely
used anticancer agents which display resistance in cells
lacking a functional mismatch repair (MMR) system
[10,11]. MMR defects have been also reported to induce
resistance to alkylating agents [12,13].
Nemorubicin is a 3’-deamino-3’[2-(S)-methoxy-4-
morpholinyl] derivative of doxorubicin which has a 2-S-
methoxymorpholinyl group at position 3’ of the sugar
moiety of doxorubicin. Nemorubicin is active in vitro as
well as in vivo against murine and human tumor cell
lines resistant to doxorubicin, to other P-glycoprotein
and multidrug resistance protein (MRP) substrates and
to topoisomerase II inhibitors [14-16]. It is also more
potent than the parent drug and retains activity in
tumors resistant to alkylating agents and topoisomerase
I inhibitors. All these features strongly suggest that
nemorubicin, although structurally an anthracycline
derivative, has a completely different mechanism of
action. Evidence that its activity can be enhanced by
incubation with cytochrome P450 enzymes, particularly
CYP3A, further differentiates its mechanism of action
from classical anthracyclines [17]. The P450-dependent
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active or more potent than the parent drug. Among
these, 3’-deamino-3”,4’-anhydro-[2"(S)-methoxy-3"(R)-
hydroxy-4"-morpholinyl] doxorubicin (PNU-159682) has
been isolated and synthesised; its potency in vitro is
more than 1000 times that of the parent drug and it
shows high antitumor activity in vivo with a spectrum of
efficacy superimposable to that of nemorubicin [18].
Nemorubicin is under clinical evaluation for loco-regio-
nal therapy in hepatocellular carcinoma (HCC). In
Phase I-II trials nemorubicin as single agent was effec-
tive against HCC patients; currently, phase I-II studies
in combination with cisplatin are ongoing.
A murine cell line resistant to nemorubicin has been iso-
lated and did not show cross-resistance to doxorubicin,
topoisomerase I and II inhibitors, 5-FU, or vinblastine
[19]. Interestingly, nemorubicin-resistant cells were hyper-
sensitive to alkylating agents including melphalan, mito-
mycin C, platinum derivatives and nitrosoureas. All these
characteristics prompted us to study the mechanism of
action of nemorubicin in details, particularly the role of
DNA repair mechanisms in its cytotoxicity.
Results
We tested the activity of nemorubicin in vitro in a CHO-
derived system with defined NER defects (Figure 1A).
Nemorubicin was less active in CHO-UV96 (lacking a
functional ERCC1) and CHO-UV61 (defective in CSB/
ERCC6) cells than parental AA8 cells. CHO-UV96 cells
transfected with the human ERCC1 gene (ERA5) showed
a restored NER function [8]; in this cellular system, sensi-
tivity to nemorubicin greatly increased over CHO-UV96
deficient cells, approaching that found in parental CHO
cells. A pair of isogenic murine leukemia cells were pre-
viously studied, L1210/0 (with defective NER function
because of an XPG defect) and L1210/DDP (more
UV-resistant because of restored NER function) [20]. We
found that nemorubicin was more active in the L1210/
DDP cells with intact NER than in the XPG-deficient
L1210/0 cells (Figure 1B).
The effects on cells with defects in NER, were also
tested for the potent nemorubicin metabolite [18],
PNU-159682. The data reported in additional file 1
clearly show that the metabolite behaves as nemorubi-
cin, being more active in cells with an intact NER.
These effects have been found both in the CHO-derived
clones and in the L1210 isogenic system used for
nemorubicin.
We employed a murine L1210-derived cell line resis-
tant to nemorubicin (L1210/MMDX) [19], and further
characterised the sensitivity of parental and resistant
cells to agents whose activity is influenced by NER.
Nemorubicin-resistant cells were cross-resistant to the
marine compound trabectedin, whose activity is NER-
dependent [8,9], (Figure 1C) and the resistance index
was similar to the one for nemorubicin. Treatment of
these cells with UV light showed that nemorubicin resis-
tant cells were four times more sensitive than parental
cells to UV (Figure 1D).
Using the host cell reactivation assay, we tested the
NER-dependent ability of parental and nemorubicin-
resistant L1210 cells to repair a damaged plasmid.
Figure 2A shows that nemorubicin resistant cells were
much less able to repair the lesions induced by UV than
parental cells, indicating that NER impairment is likely
in these cells.
We therefore analysed the expression of proteins
involved in NER in parental and resistant cells and
found that both L1210 nemorubicin-sensitive and resis-
tant cells expressed comparable levels of ERCC1 and
XPA (Figure 2B), while no XPG protein could be
detected in resistant cells. L1210 nemorubicin-resistant
cells were transfected with the human XPG cDNA and
two independent clones re-expressing XPG were
selected for testing the drug’s activity. The two clones
expressed the human XPG, as assessed by western blot-
ting analysis (Figure 2C). The introduction of human
XPG in L1210/MMDX cells was able to recover the
compromised ability of these cells to repair UV-
damaged plasmid (additional file 2). In both clones,
restoration of XPG expression and function was asso-
ciated with a restoration of nemorubicin activity, with
an IC50 similar to the one in parental cells (Figure 2C).
Having shown that XPG defects are likely to be
responsible for the resistance of these cells to nemorubi-
cin, we analysed the molecular mechanisms responsible.
A mutation in the XPG gene leading to premature stop
codon was observed in a human cancer cell line made
resistant to trabectedin [9]. We tested for mutations in
the murine XPG gene of L1210 resistant to nemorubi-
cin. Scanning the entire coding region of the gene and
comparing the sequence with the one present in Gene-
Bank, we did not find any mutations leading to a stop
codon. By real time RT-PCR the mRNA levels of XPG
in parental and resistant cells were analysed. The
expression of XPG mRNA was negligible in the resistant
cells (Figure 2C).
The lack of XPG mRNA expression prompted us to
verify whether epigenetic mechanisms such as methyla-
tion of the promoter might account for the gene silen-
cing. The murine XPG promoter contains a putative
CpG island (Figure 3A) and primers were specifically
designed to determine the methylation status of the pro-
moter using methylation specific PCR. The results
clearly indicate that the XPG promoter region analysed
is methylated in nemorubicin-resistant cells (Figure 3B).
To further assess the importance of XPG methylation
in determining resistance to nemorubicin, we analysed
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Page 2 of 12the expression of XPG mRNA and protein in L1210
parental and nemorubicin resistant cells treated with
the demethylating agent 5’aza-deoxycytidine (AZA). This
drug did not modify either the mRNA levels or
the protein expression of XPG in parental L1210 cells
(Figure 3C). In L1210-nemorubicin resistant cells, AZA
partially induced the re-expression of XPG both at RNA
and protein level. This increase paralleled the restoration
of the sensitivity to nemorubicin (Figure 3D). Pretreat-
ment with 5nM AZA for 72 hours alone induced in
L1210 cells a reduction in growth and an increased activ-
ity when combined with nemorubicin. In L1210/MMDX
cells, the pretreatment with AZA was able to revert the
resistance to nemorubicin and the activity of the drug
was similar to that observable in L1210 parental cells.
Although the expression of XPG in L1210/MMDX cells
treated with AZA did not reach the level present in
L1210 parental cells, it was sufficient to repair UV-
damaged plasmid with an efficiency similar to that of
parental NER proficient cells (additional file 3).
To select human-derived cancer cells for resistance to
nemorubicin we isolated clones resistant to the drug
from the human colocarcinoma cell line HCT116. We
picked five independent clones which had a resistant
index (from 2.3 to 3.1) similar to the one reported for
murine cells (Figure 4A). Analysing the expression of
Figure 1 Activity of nemorubicin in cells with NER defects. Panel A. Inhibition of colony formation in CHO isogenic cells AA8 with a wt NER
(black circle), CHO-UV96, black triangle) lacking the expression of ERCC1, CHO-UV61 (black square) lacking the expression of CSB/ERCC6 and
ERA5 (white square) derived from UV96 in which the human ERCC1 gene was transfected and the NER activity restored. Results are reported as
percentages of the inhibition relative to untreated cells and are the mean and SD of at least three replicates. Panel B. Activity of nemorubicin in
L1210 cells with functional NER (L1210/DDP, black circle ) and NER defective L1210/0 (black square). Results are reported as percentages of the
inhibition relative to untreated cells and are the mean and SD of at least three replicates. Panels C and D. Response of L1210 parental cells and
of L1210 nemorubicin-resistant cells (L1210/MMDX) to UV (Panel D) and trabectedin (Panel C). Cells were treated with different concentrations of
trabectedin or different UV doses and counted 72 hours later. The values are the mean +/- SD of three replicates. L1210 parental cells (black
circle), L1210/MMDX cells (black square).
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clones lacked XPG protein expression, but retained
ERCC1 and XPA expression similar to parental cells
(Figure 4B). The nemorubicin-resistant clones had
increased sensitivity to UV rays (Figure 4C), but were
equally susceptible to gamma rays (Figure 4D). The XPG
gene was scanned and compared with the human XPG
gene sequence present in GeneBank, and no mutations
were found. HCT116 derived clones also displayed a 20-
35% lower expression level of XPG mRNA, as detected
by real time RT-PCR, than parental cells (Figure 5A).
Analysis of the human XPG promoter revealed the pre-
sence of putative CpG islands (Figure 6A) which were
analysed for methylation. In the regions selected methyla-
tion-specific PCR indicated no methylation (data not
shown). Although we could not detect methylation in the
HCT116 resistant clones despite a reduction in XPG
mRNA levels, AZA treatment boosted the activity of
nemorubicin in resistant clones but not in parental cells
(Figure 5B), suggesting a small but appreciable role of
methylation in this system as well. This same treatment
with 5’aza-deoxycytidine, induced a very little re-appear-
ance of XPG protein (additional file 4). One of the clones
(M23) was selected for in vivo studies. Both sensitive and
resistant cells grew at similar rate in vivo. M23 cells
were found to be resistant to nemorubicin in vivo too
(Figure 5C).
To verify whether the methylation of human XPG
promoter could be detected in human samples too, we
checked its status by methylation-specific PCR in 26
ovarian cancer DNA samples and the corresponding
normal blood DNA. We found methylation in 5 out of
the 26 tumor samples (approximately 20%), but not in
blood DNA. Figure 6B reports a representative PCR
Figure 2 NER Activity in sensitive and resistant L1210 cells. Panel A. Host cell reactivation assay: L1210 parental cells (black circle), L1210/MMDX
cells (black square). Panel B. Western blot analysis for the expression of NER-belonging genes ERCC1, XPA and XPG in parental (wt), nemorubicin
resistant L1210 cells (MMDX), L1210/0 and L1210/DDP cells. Panel C. Western blot analysis for the expression of XPG in parental (L1210), nemorubicin
resistant L1210 cells (MMDX), and in L1210/MMDX clone 5 (CL5) and clone 6 (CL6). Panel D. In vitro growth inhibition induced by nemorubicin in
L1210 parental (black circle), L1210/MMDX (black square) cells and in two clones derived from L1210/MMDX (clone 5, (white triangle) clone 6 (white
rhomb) ) in which the human XPG gene has been transfected. The values are the mean +/- SD of three replicates performed in three independent
experiments. Panel E. Expression of XPG mRNA in L1210 parental and in L1210/MMDX cells measured by Real Time RT-PCR.
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Page 4 of 12result in these patients. Direct bisulfite sequencing con-
firmed the cytosine methylation in these samples (data
not shown). Analysis of the XPA gene (Figure 6C) did
not show any evidence of methylation beside the pre-
sence in its promoter of putative CpG islands.
Discussion
Defects in DNA repair mechanisms are usually associated
with greater sensitivity to anticancer agents [20-22]. Two
major exceptions have been reported: defects in the
MMR reduce the activity of cisplatin, carboplatin and
alkylating agents, while defects in NER have been asso-
ciated with a loss of susceptibility to treatment with the
marine compound trabectedin, an interesting new drug
currently under clinical investigation.
We have shown here that nemorubicin, a doxorubicin
derivative currently in clinical evaluation, acts through a
similar mechanism to trabectedin, requiring an intact
NER system to exert its activity. Nemorubicin is an
anthracycline derivative differing from doxorubicin for
the presence of a 2-S-methoxymorpholinyl group in
position 3’ of the aminosugar. Doxorubicin has been
reported to be more active in fibroblasts isolated from
patients with defects in NER due to mutations in the
XPD gene compared to human fibroblasts isolated from
normal donors [23]. In the same isogenic system used
for the experiments presented here, doxorubicin was
found to be equally or only marginally more active in
NER defective cells compared to wt, NER proficient
cells (ratio of IC50 s in cells with NER defects and wt
cells ranging from 1.2 to 1.4) [24]. The evidences
reported here, together with the published lack of cross
resistance with doxorubicin [19] make nemorubicin a
compound clearly acting with a mechanism different
Figure 3 Methylation analysis in L1210 murine model. Panel A. Analysis of murine XPG promoter and identification of putative CpG islands
from which primers for methylation specific PCR were designed. Panel B. Methylation specific PCR in L1210 sensitive (wt) and resistant cells
(MMDX). M: methylated, U: unmethylated. Panel C. Expression of XPG mRNA and protein in L1210 parental and L1210/MMDX cells untreated or
treated for 72 hours with 50 nM AZA. Panel D. Growth inhibitory activity of nemorubicin in L1210 parental (black circle) and L1210/MMDX (black
square) cells without (up) or with (bottom) 50 nM AZA. Cells were pretreated with AZA for 72 hours before the addition of nemorubicin.
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an intact NER system for nemorubicin activity has been
demonstrated in murine and human cell lines. Further-
more we have found that cells, both murine and human,
made resistant to nemorubicin show a defect in NER
associated with the loss of expression of XPG. Cells
resistant to nemorubicin are cross-resistant to trabecte-
din, although from a structural point of view, trabecte-
din and nemorubicin do not share similarities. Cell lines
made resistant to trabectedin showed a multidrug-resis-
tant phenotype [25,26] while nemorubicin did not
induce this phenotype and cells resistant to doxorubicin
through overexpression of MDR-1 retain sensitivity to
nemorubicin [14,15]. Our findings indicate that
nemorubicin, although structurally related to doxorubi-
cin, acts with a different mechanism of action and this
could influence the clinical development of the drug. In
particular, our data show that at least in vitro, the resis-
tance to nemorubicin involves XPG and is reversible.
This could be an advantage in the clinic since there is
the possibility to revert the methylation and possibly the
resistance by demethylating treatments as reported for
carboplatin [27].
As for the mechanism of inactivation of XPG found in
nemorubicin-resistant cells, we did not find mutations
in both human and murine XPG gene in resistant cells.
The human cell line we made resistant to nemorubicin,
the colocarcinoma derived HCT116, is the same human
Figure 4 Studies in parental and nemorubicin resistant human HCT116 cells. Panel A. Inhibition of colony formation induced by
nemorubicin in HCT116 parental cells (black circle) or resistant clones M1 (black square), M7 (white circle), M12 (black triangle), M14 (white
square), M23 (white triangle). Results are reported as percentages of growth inhibition relative to untreated cells and are the mean and SD of at
least three replicates. Panel B. Western blot analysis for the expression of NER-belonging genes ERCC1, XPA and XPG in parental and
nemorubicin-resistant cells. Response of HCT116 parental cells (black circle) or resistant clones M1 (black square), M7 (white circle), M12 (black
triangle), M14 (white square), M23 (white triangle) to UV treatment (Panel C) or g-rays (Panel D). Results are reported as percentages of growth
inhibition relative to untreated cells and are the mean and SD of at least three replicates.
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Page 6 of 12Figure 5 In vitro and in vivo activity of nemorubicin in sensitive and resistant HCT116 cells. Panel A. Expression of XPG mRNA in HCT116
parental and five nemorubicin-resistant cells measured by Real Time RT-PCR. Results are reported as decrease over untreated cells and are the
mean and SD of at least three replicates. Panel B. In vitro cytotoxic activity of nemorubicin in parental HCT116 (black circle) and M23-resistant
(black square) cells without (left) or with (right) 100 nM AZA. Panel C. In vivo activity of nemorubicin in mice transplanted with parental HCT116
(left) or the M23-resistant clone (right). Data are reported as tumor volume determined by measurement of the tumor diameters for untreated
(black circle) or nemorubicin-treated (black square) mice. Each group consisted of 8 animals and each point represents the mean +/- SD.
* p < 0.01 relative to untreated animals.
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Page 7 of 12cancer cell line made resistant to trabectedin [9] for
which a mutation in the XPG gene leading to premature
stop codon was observed.
We have provided evidence that methylation of the
XPG promoter is responsible for a lack of transcription
of the gene in murine cells with resistance to nemoru-
bicin. Promoter methylation is an important mechan-
ism of gene silencing with a key role in cancer
development where it can progressively reduce the
expression of tumor suppressor genes favouring tumor
initiation and progression [28-30]. In addition, an
important example of methylation as a mechanism of
induction of drug resistance is found in some cispla-
tin-resistant cells where the mismatch repair gene
hMLH1 can be inactivated through this mechanism
[31,32]. We herein report the first evidence of a
methylation-dependent silencing of the NER belonging
XPG gene. This mechanism is not restricted to a single
experimental system, as it was observed in all the cells
selected for resistance to nemorubicin. It is to note,
however, that in the human colocarcinoma cell line
HCT116 additional mechanisms responsible for XPG
silencing are present. In fact, in these cells XPG pro-
tein expression is lost although mRNA expression can
still be detected. These data, together with the lack of
XPG methylation found in the DNA region analysed,
would indicate that DNA methylation does not play a
role in the XPG inactivation in these cells. However,
the fact that pretreatment of nemorubicin-resistant
HCT116 cells with 5’aza-deoxy-cytidine induces a
small but appreciable increase in both activity and
expression of XPG protein, would suggest that methy-
lation could be present in CpG islands beside those
analysed here. Clearly, the absence of XPG protein
expression in the resistant clones would only partially
be ascribable to this mechanism and post-trascriptional
mechanisms not yet identified are more likely to play a
role in these cells.
Figure 6 Methylation of XPG promoter in human tumors. Panel A. Analysis of human XPG promoter and identification of putative CpG
islands from which primers for methylation specific PCR were designed. Panel B. XPG Methylation specific PCR in tumor and blood samples
from patients with ovarian cancer. Samples in which methylated DNA was detectable have been highlighted. Panel C. XPA Methylation specific
PCR in the same tumor samples used for XPG methylation analysis.
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clinical specimens where a substantial percentage of
never treated ovarian cancers had low but detectable
XPG methylation. In a small subset of patients, we
could also measure the XPG mRNA levels. Although
the number of samples analysed did not allow a proper
statistical analysis, the results obtained in 5 XPG methy-
lated and 9 XPG unmethylated samples showed that
XPG mRNA levels in unmethylated samples were 1.5
fold higher than those in the methylated ones (data not
shown).
The epigenetic-mediated induction of resistance opens
up the possibility, as shown here in vitro,t or e v e r tt h e
resistance phenotype using the drugs in combination
with demethylating agents, already in clinical use. In
addition, this mechanism of resistance has the advantage
of inducing a particular sensitivity to DNA damaging
agents such as platinum derivatives. The combination of
nemorubicin and cisplatin is currently under clinical
investigation and the first step of a phase II study in
patients with hepatocellular carcinoma showed promising
activity with good tolerability [33]. The evidence that
XPG can be methylated in ovarian cancer samples, where
platinum-containing regimens are used in first line, could
help identify patients (with high XPG methylation) who
are likely to benefit most from a platinum-based therapy,
with a lower risk of relapse. This hypothesis is supported
by the evidence that XPG expression has already been
associated with response in ovarian and lung cancer
[34,35]. Our cells lacking XPG are hypersensitive both to
UV damage and cisplatin. The role of XPG methylation
in determining response to platinum containing regimens
needs to be tested in a larger cohort of patients with
ovarian cancer.
Materials and methods
Chemicals
Nemorubicin hydrochloride and PNU-159682 were
synthesized at Nerviano Medical Sciences (Nerviano,
Italy). Trabectedin was kindly supplied by PharmaMar
(Colmenar Viejo, Madrid, Spain). 5’aza-deoxycytidine
was purchased from Sigma.
Stock solutions were prepared in water or DMSO and
stored at -20°C
Cells and drug-induced cytotoxicity
Chinese hamster ovary (CHO)-derived cells with specific
defects in NER activity (UV96, UV61), kindly provided
by Dr M Stefanini [24] were maintained in F10 medium
supplemented with 10% FBS. Stably ERCC1-transfected
CHO cells (ERA5, generated in our laboratory) were
maintained in the same medium containing G418
500 μg/ml [8]. For clonogenic assays, cells were plated
at 150 cells/ml and after 48 hours were treated for
1 hour with different drug concentrations. Colonies
were stained with 1% crystal violet (Sigma-Aldrich) after
7-10 days and counted using the Entry Level Image ana-
lysis system (Immagini & Computer, Bareggio, Milan,
Italy).
L1210 parental cells and L1210 cells resistant to
nemorubicin [19], L1210/0 and L1210/DDP (kindly
provided by Dr Wood [20]) were maintained in RPMI.
Cells from each well were counted using a cell culture
counter (Coulter Channelyser® 256, Beckman Coulter).
Cells were seeded at 100.000 cells/ml and after 24 hours
treated with different drug concentrations for 1 hour.
The average number of cells from three wells deter-
mined 72 hours after treatment was used to assess
growth rates. The mean ± SD is shown.
Human colocarcinoma cells HCT116 (obtained from
American Type Culture Collection, Rockville, MD,
USA), were maintained in ISCOVE’s modified medium.
Clones resistant to nemorubicin were obtained by
culturing the cells in the constant presence of the drug.
A clonogenic assay was used to determine drug activity.
Parental HCT116 cells and five different clones
(M1, M7, M12, M14, M23) were plated at 300-400
cells/well in six-well plates; 24 hours after seeding, dif-
ferent drug concentrations were added for 24 hours.
The colonies formed were stained approximately two
weeks later with 10% crystal violet in 20% ethanol.
IR treatments were made using Rad Gil Machine
(Gilardoni - Italy) - UV treatment was performed using
a UV lamp set at a dose of 100 J/sec.
Treatments with 5’aza-deoxycytidine were performed
by adding the drug for 72 hours to L1210 and HCT116
cells at 50 and 100 nM, respectively. At the end of treat-
ment, cells were harvested for molecular analysis or
re-seeded for the determination of nemorubicin activity
as described above.
In vivo activity
Female athymic NCr-nu/nu mice (6 weeks old) were
obtained from Harlan Italy (Udine, Italy). Mice were
maintained under pathogen-free conditions and pro-
vided with food and water ad libitum. Procedures invol-
ving animals and their care are conducted in conformity
with the institutional guidelines that are in compliance
with national (D.L. n.116, G.U., suppl.40, 18 Febbraio
1992, Circolare No. 8, G.U., July 14, 1994) and interna-
tional laws and policies (EEC Council Directive 86/609,
OJ L 358,1, December 12, 1987; Guide for the Use of
Laboratory Animals, U.S. National Research Council,
1996). 5 × 10
6 exponentially growing HCT116 cells
(parental and M23 resistant clone) were injected per
mouse subcutaneously. Nemorubicin was dissolved in
sterile water and administrated i.v. at the dose of
0.05 mg/kg for each treatment (q7 d × 3) in a volume of
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(W) of the tumor mass were measured by caliper twice
weekly and the tumor volume (TV) was calculated as
TV = (L × W2)/2, being W < L. Differences in tumor
growth between treated and untreated mice were com-
pared by ANOVA analysis
Host cell reactivation assay
Purified pGL2 plasmid was damaged with UV light
(140 J). L1210 WT and L1210/MMDX cells were trans-
fected with 5 μg of UV-treated pGL2 and 0.5 μgo f
untreated pRL-SV40 used for internal normalization
using lipofectamine. Reporter gene activities were evalu-
ated after 6, 24 and 48 h, using the Dual Luciferase
system (Promega, Milan, Italy). Results are expressed as
the percentage of the control luciferase reported activity
normalized by the renilla activity value. The mean ± SD
of three independent experiments is shown.
Western blotting
For Western blot analysis, cells were lysed in ice-cold
lysis buffer (50 mM tris pH8, 150 mM NaCl, 1 mM
EGTA, 100 mM NaF, 10% glycerol, 1 mM MgCl2 and
1% Triton X-100) containing protease inhibitors (Sigma)
and incubated on ice for 30 minutes. Samples were cen-
trifuged at 13000 × g for 10 min at 4°C and the protein
content of the supernatant was determined using a Bio-
Rad Protein assay (Bio-Rad).
Forty μg of total cellular protein were resolved by SDS-
PAGE on 8% polyacrylamide gel and electrotransferred
to PVDF membrane. Immunoblot analysis was done
using the following antibodies: anti XPG (Oncogene
Research), anti XPA (FL-273) anti ERCC1 (FL-297) goat
anti-actin and anti tubulin (H-235) (Santa Cruz Biotech-
nology). Membranes were then reacted with secondary
antibodies (1:3000, Santa Cruz Biotechnology) and devel-
oped using the ECL kit (Amersham Biosciences).
Real time RT PCR
Real Time RT-PCR was used for relative quantification
of XPG mRNA. Three hundred ng of total RNA purified
with the SV40 Total RNA Isolation System (Promega)
were retrotransrcibed in 20 μlw i t ha nA r c h i v eK i t
(Applied Biosystems) and 2 μl were amplified by Real
Time PCR (ABI Prism 7900 Sequence Detection System,
Applied Biosystems). XPG expression was detected
using a commercial, TaqMan based, Assay by Design
(M500164482, Applied Biosystems). Primers and Taq-
Man probe sequences to detect the actin mRNA levels
were supplied as a ready-to-use solution (Applied Bio-
systems). Reactions were run in a total volume of 25 μL
with TaqMan PCR Master Mix, following the manufac-
turer’s instructions (Applied Biosystems).
Mutation analysis
After genomic DNA extraction by using Maxwell 16
Cell DNA Purification Kit, exons amplification were per-
formed by PCR with different couple of primers, for
both human and murine XPG, listed in additional file 5.
PCR reactions were subjected to initial incubation at
95°C for 2 minutes, followed by 35 cycles of 95°C for 30
seconds, 54°C for 30 seconds and 72°C for 1 minute.
Final extension was done by incubation at 72°C for
5 minutes. PCR products were separated on 1.5% agar-
ose gels and visualized after ethidium bromide staining.
Visualized bands were collected from gel, extracted and
sequenced by using forward and reverse primers used
for amplification. DNA sequencing were performed by
PRIMM srl (Milan, Italy).
Methylation specific- PCR
Genomic DNA was extracted for methylation analysis
from cells in culture or frozen tissues by using Maxwell
16 Cell or Tissue DNA Purification Kit, respectively. One
microgram of genomic DNA was modified with sodium
bisulfite using the Epitect Bisulfite kit (Qiagen) according
to the specifications of the manufacturer. Methylation-
specific PCR (MSP) was run in a total volume of 25 μL
by using AmpliTaq Gold (Applied Biosystems). MSP
reactions were subjected to initial incubation at 95°C for
5 minutes, followed by 35 cycles of 95°C for 30 seconds,
and annealing at the appropriate temperature for 30 sec-
onds and 72°C for 30 seconds. Final extension was done
by incubation at 72°C for 5 minutes. MSP products were
separated on 2% agarose gels and visualized after ethi-
dium bromide staining. To verify successful bisulfite
modification of the DNA, a region of the Calponin pro-
moter region was amplified with every modified DNA
sample. The following primers were used:
Human XPG
Unmethylated Forward 5’-TTTGTGGATTTATTAGT-
GAAGGTGGG-3’ Unmethylated Reverse 5’-ATAAAAA-
CACATTAAAACAAAAAAAC-3’ Methylated Forward
5’-GCGGATTTATTAGCGAAGGCGG-3’ Methylated
Reverse 5’-CACTAATAAAAACGCATTAAAACGAA-3’
Human XPA
Unmethylated Forward 5’-TAATTTGTGGAGTTT
GTTTTG-3’ Unmethylated Reverse 5’-CATTAACCA-
TACCTCCAATAACCAC-3’ Methylated Forward
5’-TCGCGGAGTTGTTTGTTTC-3’ Methylated Reverse
5’-ATTAACCATACCTCCAATAA CC-3’.
Murine XPG
Unmethylated Forward 5’-AGGTATAGATTTAAAATT-
GAATTGT-3’, Unmethylated Reverse 5’-CTCTTAAC
TTCCAAATAAACACAAA-3’, Methylated Forward 5’-
AGGTATAGA TTTAAAATCGAATCGT-3’, Methylated
Reverse 5’-CTTAACTTCCAAATAAACGCGAA-3’.
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Page 10 of 12DNA samples were obtained from 26 ovarian tumors
(22 stage III and 4 stage I, as histotype: 18 serous, 3
endometroid, 2 mucinous, 1 clear cell, 1 undifferen-
tiated, 1 germinal) derived form patients never treated
with chemotherapy or radiotherapy. For these samples,
together with methylation specific PCR, direct bisulfite
sequencing was used to confirm the presence of methyl-
cytosines.
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